


SUPPLEMENTARY FIGURE



Supplementary Figure 1. Non-squamous NSCLC patients with EPHA5 mutation had better clinical response and outcome after ICI therapy. All patients with EPHA5 mutations (A) presented durable clinical benefit to ICIs, and (B) had high TMB. (C) The EPHA5-Mut group tended to have longer PFS than the EPHA5-WT group.